Novo Nordisk: FDA approves expanded label for Ozempic
(CercleFinance.com) - The US Food and Drug Administration approved Novo Nordisk's diabetes drug Ozempic to reduce the risk of major cardiovascular events in people with type 2 diabetes and cardiovascular diseases, the Danish drugmaker said on Thursday.
The FDA has approved a label expansion based on a trial that showed that Ozempic cut the risk of death, non-fatal heart attack or non-fatal stroke by 26% versus placebo, when added to standard of care, it said.
Ozempic was first approved by the US FDA in 2017 and is now marketed in 25 countries.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The FDA has approved a label expansion based on a trial that showed that Ozempic cut the risk of death, non-fatal heart attack or non-fatal stroke by 26% versus placebo, when added to standard of care, it said.
Ozempic was first approved by the US FDA in 2017 and is now marketed in 25 countries.
Copyright (c) 2020 CercleFinance.com. All rights reserved.